Asymptomatic people with well-controlled HIV do not have abnormal left ventricular global longitudinal strain.

Autor: Hoy JF; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia., Lee SJ; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia., Trevillyan JM; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia., Dewar EM; Department of Cardiology, Alfred Health, Melbourne, VIC, Australia.; Alfred Baker Medical Unit, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Roney J; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia., Dart A; Department of Cardiology, Alfred Health, Melbourne, VIC, Australia.; Alfred Baker Medical Unit, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Yang Y; Department of Cardiology, Alfred Health, Melbourne, VIC, Australia.; Alfred Baker Medical Unit, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Jazyk: angličtina
Zdroj: Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 Jul 20; Vol. 10, pp. 1198387. Date of Electronic Publication: 2023 Jul 20 (Print Publication: 2023).
DOI: 10.3389/fcvm.2023.1198387
Abstrakt: Background: Previous studies have reported impairment in systolic and diastolic function in people with HIV (PWHIV). Our aim was to determine if echocardiographically measured left ventricular (LV) global longitudinal strain (GLS) is abnormal in asymptomatic PWHIV.
Methods: A cross-sectional study of PWHIV ( n  = 98, 89% male, median age 53 years) and HIV-negative people ( n  = 50, median age 53 years) without known cardiovascular disease were recruited from a single centre. All participants completed a health/lifestyle questionnaire, provided a fasting blood sample, and underwent a comprehensive echocardiogram for assessment of diastolic and systolic LV function, including measurement of GLS.
Results: All PWHIV were receiving antiretroviral therapy (ART) for a median of 12 years (IQR: 6.9, 22.4), the majority with good virological control (87% suppressed) and without immunological compromise (median CD4 598 cells/µl, IQR: 388, 841). Compared with controls of similar age and gender, there was no difference in GLS [mean GLS -20.3% (SD 2.5%) vs. -21.0% (SD 2.5%), p  = 0.14] or left ventricular ejection fractions [65.3% (SD 6.3) vs. 64.8% (SD 4.8), p  = 0.62]. Following adjustment for covariates (gender, heart rate, systolic and diastolic blood pressure, and fasting glucose), the difference in GLS remained non-significant. There were no differences in LV diastolic function between the groups. Exposure to at least one mitochondrially toxic ART drug (didanosine, stavudine, zidovudine, or zalcitabine) was not associated with impairment of LV systolic function.
Conclusion: No clinically significant impairment of myocardial systolic function, as measured by LV GLS, was detected in this predominantly Caucasian male population of PWHIV on long-term ART, with no history of cardiovascular disease.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(© 2023 Hoy, Lee, Trevillyan, Dewar, Roney, Dart and Yang.)
Databáze: MEDLINE